What really drives vaccine uptake? Trust, knowledge and perceived risk
This study applies an extended Theory of Planned Behavior model in Hungary to examine how trust in science, what people know, and how they perceive COVID-19 risks relate to vaccination intentions and behavior. By integrating these factors into a single behavioral framework, the analysis aims to clarify which levers best predict uptake beyond demographics alone, and how cognitive and trust-related variables may shape decisions.
Why it might matter to you:
If you work on population behavior around preventive health, this kind of model can help you distinguish between information deficits and credibility deficits when designing interventions. It can also inform how you specify mediators in evaluation—separating perceived risk from trust-related pathways—so program effects are easier to interpret and compare across contexts.
Indonesia’s mass health screening: early signals, big policy stakes
This Nature Health piece reports early insights from Indonesia’s large-scale health screening programme. While details in the available extract are limited, the focus is on what initial implementation is revealing—an early readout that can shape how such programmes are refined, scaled, and integrated with follow-up care and health-system capacity.
Why it might matter to you:
Large screening programmes can shift the measured burden of chronic and nutrition-related conditions by changing who gets diagnosed and when, which matters for trend interpretation. Early implementation insights can help you anticipate where selection effects, bottlenecks, or drop-off in linkage-to-care could bias outcomes—and where economic evaluation should include real-world delivery constraints.
Postpartum haemorrhage: cheap prevention, costly referrals
A cross-sectional survey of 31 public hospitals in Zambia assessed availability and direct costs of WHO-recommended postpartum hemorrhage (PPH) interventions, and compared an “ideal” treatment pathway at a well-equipped primary facility with a referral pathway to tertiary care. Among 74,238 deliveries, PPH prevalence was 2.6% with 4.8% fatality among cases; tranexamic acid was available in 58.1% of hospitals at a subsidized cost of US$1.91 per dose. Managing severe PPH via referral was estimated to cost about 18.6% more than the ideal pathway, translating to an avoidable annual national burden when scaled.
Why it might matter to you:
This is a concrete example of how commodity gaps and system fragmentation convert preventable events into higher downstream costs—useful when arguing for upfront investment in essential inputs. The pathway-based costing also offers a template for evaluating other time-sensitive conditions where primary-level readiness can change both mortality and budget impact.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
